Coherus BioSciences, Inc. (CHRS) News
Filter CHRS News Items
CHRS News Results
|Loading, please wait...|
CHRS News Highlights
- For CHRS, its 30 day story count is now at 21.
- Over the past 11 days, the trend for CHRS's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- BODY, LEE and PD are the most mentioned tickers in articles about CHRS.
Latest CHRS News From Around the Web
Below are the latest news stories about Coherus BioSciences Inc that investors may wish to consider to help them evaluate CHRS as an investment opportunity.
Coherus BioSciences, Inc. (CHRS) Q4 2021 Earnings Conference Call February 17, 2022 5:00 PM ET Company Participants Denny Lanfear - President, Chief Executive Officer and Chairman McDavid Stilwell - Chief Financial Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Conference Call Participants Salim Syed -...
Coherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on Benzinga.com
Coherus BioSciences press release (NASDAQ:CHRS): Q4 Non-GAAP EPS of -$0.46 beats by $0.08. Revenue of $73.37M (-33.6% Y/Y) misses by $9.24M. Cash and cash equivalents were $417.2 million as of December 31, 2021, compared to $541.2 million as of December 31, 2020. 2022 Guidance: Coherus projects combined R&D and SG&A expenses...
– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – – UDENYCA ® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET –
CHRS earnings call for the period ending December 31, 2021.
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (NASDAQ:CHRS) is scheduled to announce Q4 earnings results on Thursday, February 17th, after market close.The consensus EPS Estimate is -$0.54 (compared to $0.23 in…
REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Operations and Market Access. “Paul has a demonstrated record of success in biopharmaceutical sales and marketing, having led multiple successful commercial launches and managed blockbuster oncology brands. I am excited to n
REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Feb. 9, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 236,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.44, the closing trading price on the grant date. One Vice President level executive was granted options to p
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing fourth quarter and full year 2021 financial results, the Company will post